PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1462907
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1462907
Gene Delivery Technologies Market size was valued at USD 3,918 Million in 2023, expanding at a CAGR of 14.5% from 2024 to 2032.
The method of transferring foreign genetic material-such as DNA or RNA-into host cells is known as gene delivery. For gene delivery to cause gene expression, the host cell's genome must be reached. For gene delivery to be successful, the foreign gene delivery must stay stable inside the host cell and be able to either multiply on its own or integrate into the genome. To accomplish this, foreign DNA must be created as a component of a vector that is intended to infiltrate the target host cell and transfer the transgene to that cell's genome. Recombinant viruses and synthetic vectors (viral and non-viral) are the two types of vectors that are used to transfer genes.
Gene Delivery Technologies Market- Market Dynamics
Growing investment in new technologies to propel market demand
An increase in funding and investment in the industry that supports the research, development, and production of various techniques of gene transfer accelerates the growth in revenue even more. Currently, 70% of gene and cell therapy initiatives use viral vectors, which is driving organic revenue growth for biological delivery technologies. To meet the growing demand, the operational companies are making large investments to increase the capacity at which they can produce viral vectors. The development of new gene delivery systems has been facilitated by the introduction of several revolutionary tools for genetic modifications that have simplified the process by which the scientific community has outlined the intricate nature of disease at the genomic level. Ongoing research to create clinically appropriate vectors, both viral and non-viral, to cure crippling diseases like cancer, Alzheimer's disease, and others with state-of-the-art medicines, additionally increases the market's revenue.
Gene Delivery Technologies Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 14.5% over the forecast period (2024-2032)
Based on mode segmentation, the biological segment is expected to dominate the market over the forecast period
Based on the application segmentation, the Gene Therapy held the largest market share in 2023
Based on method segmentation, the Ex vivo segment is expected to lead the market over the projected period
Based on region, North America was the leading revenue generator in 2023
The Global Gene Delivery Technologies Market is segmented based on Mode, Application, Method, and Region.
Based on the mode, the market is categorized into Biological, Chemical and Physical. The biological segment is expected to dominate the market over the forecast period due to Yescarta's and Kymriah's enormous success. Since the first viral vector-based gene therapy products were approved, viral vectors have attracted a lot of attention. End users' approval of viral vectors as the primary delivery modality has been confirmed by the exponential rise in the number of R&D programs based on these vectors.
Based on the application, the market is divided into Infrastructure Gene Therapy, Cell Therapy, Vaccines and Research. The Gene Therapy held the largest market share in 2023 and is expected to continue the same pattern during the forecast period. The revenue generation in this category has been driven by the increasing acceptability of gene-based medicines and the resulting rise in the number of clinical research activities. Global gene therapy product approval rates are rising, which has further fueled the segment's expansion.
Based on the method, the industry is divided into Ex vivo, In vivo and In vitro. The Ex vivo segment is expected to lead the market over the projected period because of its many benefits, including reduced immunogenic reactions and the capacity to evaluate transduction efficiency before re-implantation of cells into the patient. Its excellent transduction efficiency and other qualities make it a popular choice in research environments.
Gene Delivery Technologies Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to lead the Gene Delivery Technologies market during the forecast period. In the United States, a significant number of clinical trials are being conducted to evaluate the safety and effectiveness of gene therapy as a potential treatment for HIV/AIDS, cancer, and genetic disorders. Additionally, a sizable portion of the largest businesses involved in the production and marketing of gene delivery technology have their headquarters in the United States. The region's commercial dominance in gene delivery technology can be attributed to several characteristics.
It is projected that the growing interest in gene delivery technologies among both public and private investors would hasten the entry of new firms into the market. To improve their market position, the leading companies are also implementing a number of strategic activities, including licensing, partnerships, and mergers and acquisitions. Notable mergers and acquisitions have taken place in the gene delivery technology business in the last few years.
In September 2022, Orchard Therapeutics plc, a leader in global gene therapy, and Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company (J-GSP) that develops cutting-edge medical solutions using the newest biotechnology, announced they have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics. Through this acquisition, Kyowa Kirin will be able to optimize the value of Libmeldy(R) and effectively expedite the development of Orchard Therapeutics' next-generation MPS programs in addition to its other early research initiatives, which include frontotemporal dementia (FTD) and a severe genetic form of Crohn's disease. Additionally, the combination of Kyowa Kirin's skills, resources, and infrastructure with Orchard Therapeutics' cutting-edge HSC gene therapy platform technology will facilitate the ongoing development of a number of promising biopharmaceutical candidates with the potential to provide transformative value in medical care, including in therapeutic areas and indications like autoimmune diseases and oncology where Kyowa Kirin has extensive experience.
GLOBAL GENE DELIVERY TECHNOLOGIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
QIAGEN
Vectalys
Horizon Discovery Group Co.
OriGene Technologies, Inc.
Oxford Biomedica
SignaGen Laboratories
Thermo Fisher Scientific, Inc.
Takara Bio Inc.
Bio-Rad Laboratories, Inc.
System Biosciences llc
Hoffmann-La Roche AG
Promega Corporation
Sirion-Biotech GmbH
Catalent Inc.